Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy.

ABSTRACT:

Introduction

No treatments for axonal peripheral neuropathy are approved by the United States Food and Drug Administration (FDA). Although patient- and clinician-reported outcomes are central to evaluating neuropathy symptoms, they can be difficult to assess accurately. The inability to identify efficacious treatments for peripheral neuropathies could be due to invalid or inadequate outcome measures.

Methods

This systematic review examined the content validity of symptom-based measures of diabetic peripheral neuropathy, HIV neuropathy, and chemotherapy-induced peripheral neuropathy.

Results

Use of all FDA-recommended methods to establish content validity was only reported for 2 of 18 measures. Multiple sensory and motor symptoms were included in measures for all 3 con

SUBMITTER: Gewandter JS 

PROVIDER: S-EPMC5528159 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature